PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ — PeproMene Bio, Inc. today announced the publication in The Lancet, one of the world’s leading medical journals, of results from its Phase 1 clinical trial evaluating
